PRP and Stem Cell Therapy: Where the Two Diverge — A Reading

The conflation of PRP and stem cell therapy is one of the more persistent confusions in regenerative medicine — and it is, in my reading, a conflation the Gangnam clinics have quietly stopped entertaining. The two protocols share a regenerative ambition; they share, in the brochures, an aesthetic of vials and softly lit consult rooms. What they do not share is mechanism, tier of cellular intervention, or the regulatory register under which they are administered. 呢兩樣真係兩回事, a Hong Kong clinician told me last winter from a Cheongdam consult — and she was, on the evidence, correct.

What platelet-rich plasma actually is

Platelet-rich plasma is an autologous blood product — drawn from the patient, centrifuged to concentrate the platelet fraction, and reinjected into the target tissue. The protocol is straightforward in mechanical terms. A clinician draws roughly twenty to sixty millilitres of whole blood, processes it in a closed-system centrifuge for ten to fifteen minutes, and decants the buffy-coat layer that contains a platelet concentration two to seven times the baseline serum count. The reinjection delivers a high local dose of the growth factors that platelets release during normal wound signalling — PDGF, TGF-β, VEGF, IGF-1, and the broader cytokine envelope. Patients report localised inflammation for two to four days, mild bruising at the draw site, and — depending on indication — the gradual softening of fine lines or the slow recalibration of joint mechanics over the subsequent six to twelve weeks. The protocol is, on its mechanism, a signalling intervention. The platelets do not become tissue; they prompt the tissue already present to behave more regeneratively. A 2020 review in the Journal of Cutaneous and Aesthetic Surgery describes PRP as a 'localised growth-factor delivery system,' which reads, in my view, as the cleaner phrasing. Variants exist within the PRP register itself, and patients should expect a Gangnam clinician to specify which is being administered. Pure-PRP preparations exclude leucocytes and produce a quieter local inflammatory response, while leucocyte-rich PRP (L-PRP) preserves the white-cell fraction and reads as more aggressively pro-inflammatory at the injection site. PRF — platelet-rich fibrin — adds a fibrin-matrix component that some practitioners prefer for hair-restoration protocols. The choice of variant tracks indication; the consent conversation should clarify the preparation, the centrifugation parameters, and the planned injection volume rather than treating PRP as a single undifferentiated category. Patients comparing quotations across clinics should ask, in particular, whether the platelet concentration is reported and whether activation has been added — these details, banal in appearance, materially shape the protocol's signalling profile.

What stem cell therapy is — and what it is not

Stem cell therapy, in the regenerative-medicine register that the Korean clinics use, refers to a class of protocols delivering mesenchymal stem cells — usually adipose-derived, occasionally umbilical-cord-derived under research protocols — into the target tissue or systemic circulation. The mechanism is categorically different from PRP. Where PRP delivers a signalling cocktail, stem cell protocols deliver cells that retain a degree of differentiation potential and that secrete their own paracrine envelope of growth factors and exosomes once seated in the recipient tissue. The cells, in the published literature, do not always engraft permanently; what they do reliably is modulate the local immune environment, recruit endogenous repair pathways, and — in indication-appropriate cases — contribute to tissue remodelling over a months-to-years timeline. The Korean Ministry of Food and Drug Safety [maintains an active registry](https://www.mfds.go.kr/eng/index.do) of approved cellular therapy protocols, and the regulatory register is meaningfully tighter than the one governing PRP. Patients should expect a more elaborate consent process, a longer pre-procedure laboratory work-up, and, where adipose-derived cells are used, a small lipoaspiration step that PRP does not require. The cellular product itself comes in distinguishable forms patients should learn to ask about. Stromal vascular fraction (SVF) — the minimally manipulated cellular suspension obtained directly from lipoaspirate enzymatic digestion — preserves a heterogeneous population that includes MSCs alongside other adipose-derived cells. Culture-expanded MSCs undergo laboratory passage to enrich the stem-cell population over one to three weeks before reinjection. Exosome therapy, increasingly visible in the Gangnam practices' menus, isolates the secreted cellular vesicles rather than the cells themselves and is, properly speaking, a related but distinct intervention. The Cleveland Clinic's broader patient-education material on regenerative protocols offers a usefully measured framing for patients arriving with a longevity-medicine vocabulary; the Korean register, the Cleveland reading, and the published systematic reviews converge on the point that stem cell therapy is not, on the published evidence, a generalised wellness upgrade.

The mechanism gap — signalling versus cellular intervention

The cleanest way to read the divergence is as a question of tier. PRP is a tier-one regenerative intervention — autologous, growth-factor-mediated, mechanism-of-action centred on signalling rather than on cellular repopulation. Stem cell therapy occupies a higher tier, where the intervention introduces cells that themselves participate in the regenerative process. The distinction matters more than the marketing tends to admit. A 2021 systematic review in Stem Cell Research & Therapy comparing PRP and mesenchymal stem cell protocols across orthopaedic and aesthetic indications found, broadly, that the two interventions produced overlapping early-phase outcomes — both reduced pain, both improved soft-tissue parameters in the first three to six months — but diverged at the twelve-month mark, with the stem cell arms showing more durable structural changes on imaging and the PRP arms showing more consistent symptomatic improvement without comparable structural change. The reading is, on the evidence, that the two protocols are doing genuinely different things. PRP modulates the local environment; stem cell therapy attempts to modify the tissue itself. Neither is the other's replacement; the choice between them is, properly understood, a choice between mechanisms.

Indications — where each protocol is appropriately used

PRP's accepted indications are broader and better-codified. The protocol has long-standing literature in androgenetic alopecia, in early-stage osteoarthritis of the knee and shoulder, in chronic tendinopathies — Achilles, lateral epicondylar, patellar — and in aesthetic medicine for fine-line softening, post-laser recovery, and adjunctive use with microneedling. The Mayo Clinic's [overview of platelet-rich plasma therapy](https://www.mayoclinic.org/tests-procedures/platelet-rich-plasma-injections/about/pac-20394313) provides a usefully restrained reading of the indication landscape. Stem cell therapy occupies a narrower, more carefully delineated set. In the Korean register, mesenchymal stem cell protocols are most often discussed for moderate-to-advanced knee osteoarthritis, for select autoimmune-adjacent skin conditions under specialist supervision, for systemic anti-inflammatory protocols in the longevity-medicine register, and — under research protocols — for selected orthopaedic and dermatological indications. Patients should expect indication-specific gating: a clinician offering stem cell therapy for an indication that PRP would competently address is, in the cleaner Gangnam practices, treated as a flag rather than a feature.

Comparison table — PRP versus stem cell, side by side

The categorical comparison below summarises the mechanism, source, and protocol differences without ranking the two interventions against each other; the choice is indication-driven rather than tier-aspirational, and the table is offered in that spirit. Note that figures are typical Gangnam protocol ranges and not a quotation; individual clinicians vary, and the regulatory framework around cellular products in particular is calibrated by indication.

What patients commonly conflate — and why

The conflation, in my reading, traces to three sources. The first is marketing language that treats 'regenerative' as a single tier rather than a spectrum; the second is the visual similarity of the two procedures from the consult-room side of the curtain — both involve vials, both involve injections, both follow a low-light, hospitality-grade clinic protocol. The third source is more interesting: a generation of overseas patients arrived at the Gangnam clinics with a vocabulary borrowed from longevity-medicine influencer content, in which 'stem cells' and 'PRP' were used near-interchangeably as shorthand for 'something more advanced than fillers.' The clinicians have, in response, become more pedagogical at the consult stage. A first consult at one of the older regenerative practices in Gangnam now routinely begins with a fifteen-minute mechanism explanation that would have been unthinkable five years ago. Patients report finding the explanation reassuring rather than tedious, which suggests the conflation is being read correctly — as a knowledge gap rather than as a marketing failure. The cleaner clinics treat the explanation as part of the protocol; the explanation is, in that sense, the first regenerative intervention.

Recovery, downtime, and the practical reading

Practical recovery profiles differ in ways that matter for travel-medicine planning. PRP recovery is short and predictable — local inflammation for one to three days, mild bruising that resolves within a week, an instruction to avoid anti-inflammatories for forty-eight hours so the platelet-driven inflammatory cascade is not blunted. Patients can usually fly within twenty-four to forty-eight hours of the procedure. Stem cell recovery is more involved. Adipose-derived protocols include a small lipoaspiration step — typically from the flank or the lower abdomen — that produces tenderness and minor swelling for three to seven days; the cellular product itself, once reinjected, may produce a low-grade inflammatory response for forty-eight to seventy-two hours. The Mayo Clinic and the Korean Society of Regenerative Medicine both advise a longer post-procedure window before air travel for adipose-derived cellular protocols, and the cleaner Gangnam practices build the recovery window into the itinerary at the booking stage. Patients planning a Gangnam visit primarily for stem cell therapy should expect a five-to-seven-day stay rather than the two-to-three-day window adequate for PRP; the difference is small in calendar terms and meaningful in clinical ones. The post-procedural lifestyle restrictions also differ in a way patients underestimate at the booking stage. PRP recovery permits gentle Cheongdam walking the same evening, low-impact gym work within a week, and a return to running within two-to-three weeks; the only consistent restriction is the anti-inflammatory window. Stem cell recovery, by contrast, asks patients to avoid impact loading for two-to-four weeks, alcohol for the first ten-to-fourteen days at most clinics' counsel, and significant heat exposure — saunas, the Korean jjimjilbang circuit, very hot baths — for two-to-three weeks while the cellular product seats. Patients planning to combine the visit with a broader Korean itinerary should sequence the regenerative work at the start of the trip rather than the end; the cleaner Gangnam concierge desks book it that way as a default.

How a Gangnam clinic typically frames the choice

The Gangnam consult, in its current form, frames the PRP-versus-stem-cell decision as a question of indication, expectation, and regulatory comfort rather than as a tier-aspirational upgrade. A patient presenting with early thinning at the temples will, in most cases, be offered PRP as the first-line protocol — three sessions over twelve weeks, with a maintenance schedule reviewed at six months. A patient presenting with grade-two-to-three knee osteoarthritis and a six-month horizon for symptomatic improvement will be offered the PRP-versus-MSC conversation more directly, with the clinician walking through the imaging-versus-symptomatic-outcome divergence the literature has documented. A patient arriving with a longevity-medicine framing — wanting 'a stem cell treatment' as a wellness intervention rather than as a treatment for a defined indication — will, in the cleaner practices, be redirected to a more thorough work-up and, in some cases, gently declined. The redirection is, in my reading, a feature rather than a bug. The clinics that have built durable international reputations have done so partly by being willing to say no. 唔啱條件就唔做, as the Cantonese phrasing has it — if the indication does not fit, the procedure is not offered. The standard reads as quietly luxurious in the same way the Cheongdam consult rooms read; the discipline is the protocol. The reading patients should take from this is, on the broader frame, less complicated than the marketing has made it. PRP and stem cell therapy are different mechanisms, with different evidence bases, different regulatory frameworks, different recovery profiles, and different appropriate indications. The two are not, as the influencer vocabulary has tended to render them, points along a single regenerative spectrum. Patients arriving with that vocabulary internalised should expect the cleaner clinics to slow the consult, lay out the divergence, and gate the protocol on the indication rather than on the marketing tier. The slower consult is, by some distance, the better consult. Patients should choose accordingly; the clinics that read as worth the visit are the ones that read the protocols correctly.

Frequently asked questions

Is stem cell therapy simply a more advanced version of PRP?

No, and the framing misleads. PRP delivers a concentrated cocktail of growth-factor signalling molecules; stem cell therapy delivers cells that themselves participate in tissue remodelling and immunomodulation. The two interventions sit on different mechanistic tiers, and the appropriate choice is indication-driven rather than aspirational. A clinician treating PRP and stem cell therapy as interchangeable upgrades is, in the better Gangnam practices, considered to have misread the protocols.

Can the two protocols be combined in a single visit?

Combination protocols exist, and some Gangnam practices offer them in indication-specific contexts — for example, an adipose-derived stem cell injection paired with a PRP overlay for moderate knee osteoarthritis. The combination is not, however, a default offering, and patients should expect a more elaborate consent and work-up process. Studies on combined PRP-MSC protocols are still consolidating; the cleaner clinical reading remains that combinations be offered for defined indications rather than as a generalised upgrade.

Which protocol has stronger published evidence?

PRP has the broader evidence base, simply on time-on-bench. The protocol has been studied since the early 2000s across orthopaedic, dermatological, and aesthetic indications, with multiple systematic reviews available. Stem cell therapy has a narrower but rapidly expanding literature, particularly in moderate-advanced osteoarthritis and select autoimmune-adjacent dermatological conditions. The 2021 Stem Cell Research and Therapy systematic review remains a useful reference point for the comparative reading.

Are the regulatory frameworks different in Korea?

Meaningfully so. PRP is treated as a standard autologous medical procedure with consent and protocol standards comparable to those for any minor in-clinic intervention. Mesenchymal stem cell protocols sit under the Korean Ministry of Food and Drug Safety's cellular therapy register, with stricter manufacturing, traceability, and consent requirements. Patients can expect a longer pre-procedure work-up and a more formal consent conversation for stem cell protocols.

How long does each protocol take to show results?

PRP results typically begin to soften visible parameters at four to eight weeks, with the cumulative effect plateauing at twelve to sixteen weeks after a multi-session course. Stem cell protocols show a longer arc — initial symptomatic changes at eight to sixteen weeks, with the more substantive structural remodelling readable on imaging at six to twelve months. Patients should plan their expectations against the timeline of the chosen mechanism rather than against an idealised composite.

Is one protocol meaningfully more expensive than the other?

Yes, and the differential is structural rather than negotiable. PRP runs at a routine in-clinic price point; stem cell protocols, given the cellular processing, regulatory overhead, and — for adipose-derived — the lipoaspiration component, typically cost several multiples of a comparable PRP course. The differential reflects the cost of the cellular product and the regulatory framework rather than a tier-aspirational mark-up. Patients should request itemised quotations and compare protocol-against-protocol rather than headline-against-headline.

Should patients pursue stem cell therapy purely as a longevity intervention?

The cleaner Gangnam practices counsel caution. Longevity-framed cellular protocols exist, but the indication-specific evidence is meaningfully thinner than the indication-driven literature for joint or dermatological applications. Patients pursuing stem cell therapy on longevity grounds should expect a more thorough work-up, a more measured conversation about expected outcomes, and, in some practices, a redirection to better-codified protocols. The redirection reads as conservative; in regenerative medicine, that disposition has tended to age well.